Register for email alerts and news feeds:
This journal | BMJ Group
rss
British Journal of Ophthalmology 2003;87:753-757; doi:10.1136/bjo.87.6.753
Copyright © 2003 by the BMJ Publishing Group Ltd.
British Journal of Ophthalmology 2003;87:753-757
© 2003 BMJ Publishing Group

CLINICAL SCIENCE

The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration

A Harris1, T A Ciulla2, L M Pratt1, E Rechtman1, L Kagemann1, H C Piper1 and H J Garzozi3

1 Department of Ophthalmology, Indiana University School of Medicine, IN, USA
2 Midwest-Eye Institute, Indianapolis, IN, USA
3 Department of Ophthalmology, Bnai Zion Medical Center, Haifa, Israel

Correspondence to:
Correspondence to:
Alon Harris, PhD, 702 Rotary Circle, IUMC, Indianapolis, IN 46260, USA;
alharris{at}indiana.edu

Aim: To comprehensively evaluate the effects of dorzolamide on the choroidal and retinal circulation in patients with age related macular degeneration (AMD).

Methods: In this randomised, double masked, parallel study, 36 non-exudative AMD patients were randomised in a 2 to 1 fashion to placebo versus topical dorzolamide and underwent assessment of their choroidal and retinal circulation. Scanning laser ophthalmoscope indocyanine green angiograms (ICGA) were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary region were evaluated by plotting intensity of fluorescence of each area over time. The means of the choroidal filling times and the heterogeneity of the filling times were assessed. Scanning laser ophthalmoscope fluorescein angiography (FA) was evaluated for retinal arteriovenous passage (AVP) times by plotting intensity of fluorescence of retinal vessels over time. Assessment was performed at baseline and at 4 months.

Results: Compared to placebo, AMD patients treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions (p=0.007, p=0.02, respectively). No significant difference in choroidal filling times was found in any of the perifoveal areas (p=0.9). Also, on FA assessment, treatment with dorzolamide showed no statistical differences in AVP times (p=0.19).

Conclusions: Dorzolamide may increase peripapillary choroidal perfusion in non-exudative AMD patients. Further studies are merited.

Keywords: dorzolamide; choroidal perfusion; retinal perfusion; age related macular degeneration


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Ophthalmology Jobs

Ophthalmology Jobs